Janine Schuurman

9.4k citations

98 papers · 6.9k indexed · 6 hit papers · h-index 41

Radiology, Nuclear Medicine and Imaging top 0.2%
Immunology top 0.5%
Molecular Biology top 5%
Oncology top 2%
Rheumatology top 1%

Co-authors: Rob C. Aalberse Paul W.H.I. Parren Theo Rispens Jan G. J. van de Winkel Frank J. Beurskens Aran F. Labrijn Steven O. Stapel Rob N. de Jong
Topics: Monoclonal and Polyclonal Antibodies Research (69 papers)Glycosylation and Glycoproteins Research (22 papers)Complement system in diseases (16 papers)
Cited by: Radiology, Nuclear Medicine and Imaging Immunology Immunology and Allergy
Journals: Science Proceedings of the National Academy of Sciences Journal of Biological Chemistry
Partner nations: Netherlands United States Denmark

In The Last Decade

Janine Schuurman

97 papers receiving 6.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange

2007 707 citations Janine Schuurman, Wim K. Bleeker et al. profile →
Immunoglobulin G4: an odd antibody

2009 622 citations Rob C. Aalberse, Janine Schuurman et al. Clinical & Experimental Allergy profile →
Complement Is Activated by IgG Hexamers Assembled at the Cell Surface

2014 568 citations Frank J. Beurskens, Rob N. de Jong et al. profile →
Avidity in antibody effector functions and biotherapeutic drug design

2022 141 citations Simone C. Oostindie, Janine Schuurman et al. profile →
Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy

2024 72 citations Jim Middelburg, Marjolein Sluijter et al. profile →
Impact of structural modifications of IgG antibodies on effector functions

2024 47 citations Timon Damelang, Janine Schuurman et al. profile →

Peers

Countries citing papers authored by Janine Schuurman

Since Specialization

Citations

This map shows the geographic impact of Janine Schuurman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Janine Schuurman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Janine Schuurman more than expected).

Fields of papers citing papers by Janine Schuurman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Janine Schuurman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Janine Schuurman. The network helps show where Janine Schuurman may publish in the future.

Co-authorship network of co-authors of Janine Schuurman

This figure shows the co-authorship network connecting the top 25 collaborators of Janine Schuurman. A scholar is included among the top collaborators of Janine Schuurman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Janine Schuurman. Janine Schuurman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Cancer vaccines compensate for the insufficient induction of protective tumor-specific immunity of CD3 bispecific antibody therapy 2025 ·Journal for ImmunoTherapy of Cancer ·Jim Middelburg,(unknown),Marjolein Sluijter,Katy A. Lloyd,Vitalijs Ovcinnikovs,Janine Schuurman,Sjoerd H. van der Burg,Kristel Kemper,Thorbald van Hall	2
2	T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors 2024 ·Nature Communications ·Jim Middelburg,Marjolein Sluijter,(unknown),(unknown),Katy A. Lloyd,Vitalijs Ovcinnikovs,Gijs G. Zom,Renoud J. Marijnissen,Christianne Groeneveldt,(unknown),(unknown),Sandra Heskamp,Sjoerd H. van der Burg,Tsolère Arakelian,Ferry Ossendorp,Ramon Arens,Janine Schuurman,Kristel Kemper,Thorbald van Hall	17
3	Agnostic B cell selection approach identifies antibodies against K. pneumoniae that synergistically drive complement activation 2024 ·Nature Communications ·(unknown),Bart W. Bardoel,Maartje Ruyken,Carla J. C. de Haas,(unknown),(unknown),(unknown),Piet C. Aerts,(unknown),Johannes Preiner,Renoud J. Marijnissen,Janine Schuurman,Frank J. Beurskens,Priscilla F. Kerkman,Suzan H. M. Rooijakkers	6
4	The Influence of Human IgG Subclass and Allotype on Complement Activation 2023 ·The Journal of Immunology ·Timon Damelang,Steven W. de Taeye,(unknown),(unknown),(unknown),Ninotska I. L. Derksen,(unknown),Suzanne N. Lissenberg‐Thunnissen,Suzan H. M. Rooijakkers,Ilse Jongerius,Mirjam M. Mebius,Janine Schuurman,Aran F. Labrijn,Gestur Vidarsson,Theo Rispens	21
5	C1q binding to surface-bound IgG is stabilized by C1r ₂ s ₂ proteases 2021 ·Proceedings of the National Academy of Sciences ·(unknown),(unknown),Annemarie Kuipers,Jürgen Strasser,Maartje Ruyken,Piet C. Aerts,Carla J. C. de Haas,Deniz Ugurlar,Maurits A. den Boer,Gestur Vidarsson,Jos A. G. van Strijp,Piet Gros,Paul W.H.I. Parren,Kok P. M. van Kessel,Johannes Preiner,Frank J. Beurskens,Janine Schuurman,Daniel Ricklin,Suzan H. M. Rooijakkers	39
6	Staphylococcal protein A inhibits complement activation by interfering with IgG hexamer formation 2021 ·Proceedings of the National Academy of Sciences ·Ana Rita Cruz,Maurits A. den Boer,Jürgen Strasser,(unknown),Frank J. Beurskens,Carla J. C. de Haas,Piet C. Aerts,Guanbo Wang,Rob N. de Jong,Fábio Bagnoli,Jos A. G. van Strijp,Kok P. M. van Kessel,Janine Schuurman,Johannes Preiner,Albert J. R. Heck,Suzan H. M. Rooijakkers	67
7	Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors 2021 ·Cancers ·Jim Middelburg,Kristel Kemper,Patrick Engelberts,Aran F. Labrijn,Janine Schuurman,Thorbald van Hall	99
8	Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET 2021 ·Journal of Biological Chemistry ·Joost Neijssen,Rosa M. F. Cardoso,Kristen Chevalier,(unknown),Thomas Valerius,Geoffrey M. Anderson,Sheri L. Moores,Janine Schuurman,Paul W.H.I. Parren,William R. Strohl,Mark L. Chiu	118
9	Dual Epitope Targeting and Enhanced Hexamerization by DR5 Antibodies as a Novel Approach to Induce Potent Antitumor Activity Through DR5 Agonism 2020 ·Molecular Cancer Therapeutics ·Marije B. Overdijk,Kristin Strumane,Frank J. Beurskens,Antonio Ortiz Buijsse,Claudine Vermot‐Desroches,(unknown),Thessa Kroes,(unknown),(unknown),Richard G. Hibbert,Andreas Lingnau,Ulf Forssmann,Janine Schuurman,Paul W.H.I. Parren,Rob N. de Jong,Esther C.W. Breij	36
10	Complement alone drives efficacy of a chimeric antigonococcal monoclonal antibody 2019 ·PLoS Biology ·Sunita Gulati,Frank J. Beurskens,Bart-Jan de Kreuk,Marcel Roza,Bo Zheng,Rosane B. DeOliveira,Jutamas Shaughnessy,Nancy Nowak,Ronald P. Taylor,Marina Botto,Xianbao He,Robin R. Ingalls,Trent M. Woodruff,Wen‐Chao Song,Janine Schuurman,Peter A. Rice,Sanjay Ram	62
11	CD3-Bispecific Antibody Therapy Turns Solid Tumors into Inflammatory Sites but Does Not Install Protective Memory 2018 ·Molecular Cancer Therapeutics ·(unknown),Işıl Altıntaş,Marjolein Sluijter,Sandra Verploegen,Aran F. Labrijn,Danita H. Schuurhuis,Mischa Houtkamp,J. Sjef Verbeek,Janine Schuurman,Thorbald van Hall	61
12	Monoclonal Antibodies against Epidermal Growth Factor Receptor Acquire an Ability To Kill Tumor Cells through Complement Activation by Mutations That Selectively Facilitate the Hexamerization of IgG on Opsonized Cells 2017 ·The Journal of Immunology ·(unknown),Stefanie Derer,Ralf Schwanbeck,Thies Rösner,(unknown),Frank J. Beurskens,Janine Schuurman,Paul W.H.I. Parren,Thomas Valerius	23
13	A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor–Resistant Lung Tumors 2016 ·Cancer Research ·Sheri L. Moores,Mark L. Chiu,Barbara S. Bushey,Kristen Chevalier,Leopoldo Luistro,(unknown),Randall J. Brezski,Peter Haytko,Thomas J. Kelly,Sheng‐Jiun Wu,Pauline L. Martin,Joost Neijssen,Paul W.H.I. Parren,Janine Schuurman,Ricardo M. Attar,Sylvie Laquerre,Matthew V. Lorenzi,Geoffrey M. Anderson	188
14	Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions 2016 ·The Journal of Immunology ·Erika M. Cook,Margaret A. Lindorfer,(unknown),Simone C. Oostindie,Frank J. Beurskens,Janine Schuurman,Clive S. Zent,Richard Burack,Paul W.H.I. Parren,Ronald P. Taylor	48
15	Effect of Target Dynamics on Pharmacokinetics of a Novel Therapeutic Antibody against the Epidermal Growth Factor Receptor: Implications for the Mechanisms of Action 2006 ·Cancer Research ·Jeroen J. Lammerts van Bueren,Wim K. Bleeker,Henrik O. Bøgh,Mischa Houtkamp,Janine Schuurman,Jan G. J. van de Winkel,Paul W.H.I. Parren	102
16	Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model 2003 ·Journal of Clinical Investigation ·Louise S. Villadsen,Janine Schuurman,Frank J. Beurskens,Tomas Norman Dam,Frederik Dagnæs‐Hansen,Lone Skov,Jørgen Rygaard,Marleen M. Voorhorst‐Ogink,Arnout F. Gerritsen,Marc A. van Dijk,Paul W.H.I. Parren,Ole Baadsgaard,Jan G. J. van de Winkel	138
17	Use of a chimeric ELISA to investigate immunoglobulin E antibody responses to Der p 1 and Der p 2 in mite‐allergic patients with asthma, wheezing and/or rhinitis 2002 ·Clinical & Experimental Allergy ·Ana Paula Fávaro Trombone,(unknown),Virgínia Paes Leme Ferriani,Janine Schuurman,R. C. Aalberse,Andrew M. Smith,Martin D. Chapman,L. Karla Arruda	72
18	The inter-heavy chain disulfide bonds of IgG4 are in equilibrium with intra-chain disulfide bonds 2001 ·Molecular Immunology ·Janine Schuurman,Gerrard J. Perdok,(unknown),Rob C. Aalberse	142
19	The Apparent Monovalency of Human IgG4 Is Due to Bispecificity 1999 ·International Archives of Allergy and Immunology ·Rob C. Aalberse,Janine Schuurman,Ronald van Ree	22
20	Mouse/Human Chimeric Antibodies Directed to Two Nonoverlapping Epitopes of the House Dust Mite Allergen, Der p 2 1997 ·International Archives of Allergy and Immunology ·Janine Schuurman,Gerrard J. Perdok,Rob C. Aalberse	5

About Janine Schuurman

Janine Schuurman is a scholar working on Radiology, Nuclear Medicine and Imaging, Immunology and Immunology and Allergy, having authored 98 papers that have together received 6.9k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (69 papers), Glycosylation and Glycoproteins Research (22 papers) and Complement system in diseases (16 papers). The work is most often cited by research in Radiology, Nuclear Medicine and Imaging (3.2k citations), Immunology (2.6k citations) and Immunology and Allergy (533 citations). Janine Schuurman has collaborated with scholars based in Netherlands, United States and Denmark. Frequent co-authors include Rob C. Aalberse, Paul W.H.I. Parren, Theo Rispens, Jan G. J. van de Winkel, Frank J. Beurskens, Aran F. Labrijn, Steven O. Stapel, Rob N. de Jong, Albert J. R. Heck and Wim K. Bleeker. Their work appears in journals such as Science, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact